The Law Library

Premerger Notifications - Reporting and Waiting Period Requirements (US Federal Trade Commission Regulation) (FTC) (2018 Edition) The Law Library

Premerger Notifications - Reporting and Waiting Period Requirements (US Federal Trade Commission Regulation) (FTC) (2018 Edition) The Law Library presents the complete text of the Premerger Notifications - Reporting and Waiting Period Requirements (US Federal Trade Commission Regulation) (FTC) (2018 Edition). Updated as of May 29, 2018 The Federal Trade Commission ("Commission" or "FTC"), with the concurrence of the Assistant Attorney General, Antitrust Division, Department of Justice (the "Assistant Attorney General" or the "Antitrust Division") (together the "Agencies"), is amending the Hart-Scott-Rodino Premerger Notification Rules (the "Rules") in order to provide a framework for determining when a transaction involving the transfer of rights to a patent or part of a patent in the pharmaceutical, including biologics, and medicine manufacturing industry (North American Industry Classification System Industry Group 3254) ("pharmaceutical industry") is reportable under the Hart Scott Rodino Act ("the Act," "HSR Act" or "HSR"). This final rule defines and applies the concepts of "all commercially significant rights," "limited manufacturing rights," and "co-rights" in determining whether the rights transferred with regard to a patent or a part of a patent in the pharmaceutical industry constitute a potentially reportable asset acquisition under the Act. This book contains: - The complete text of the Premerger Notifications - Reporting and Waiting Period Requirements (US Federal Trade Commission Regulation) (FTC) (2018 Edition) - A table of contents with the page number of each section